Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

08. November 2022 11:11 ET | Quelle: DynamiCure Biotechnology, LLC

DynamiCure Doses First Patients in Phase 1 Clinical Trial of Lead Antibody Candidate DCBY02 in Advanced Cancers

The lead candidate from DynamiCure’s anti-CD93 program, DCBY02 targets a wide range of metastatic solid tumors Phase 1 trial aims to assess the safety and anti-tumor activity of the candidate in...
20. September 2022 08:35 ET | Quelle: DynamiCure Biotechnology, LLC

DynamiCure Announces Appointment of Industry Veteran Peter Lasky as its First Chief People Officer

WALTHAM, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- DynamiCure, a private biopharmaceutical company translating pioneering immuno-normalization insights into a pipeline of innovative therapeutic...
22. August 2022 08:35 ET | Quelle: DynamiCure Biotechnology, LLC

DynamiCure Announces IND Clearance to Advance First Antibody Candidate from its DC-6001 Anti-CD93 Program into Clinical Development

WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- DynamiCure, a private biopharmaceutical company translating pioneering immuno-normalization insights into a pipeline of innovative therapeutic...